Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) is the only radioligand therapy approved by the U.S. Food and Drug Administration for metastatic prostate cancer, and it’s given through six infusions spaced six weeks apart. The treatment is “actually not that different from many of the infusions patients may have gone through already,” Dr. Sentana Lledo says.

The entire visit may take less than one hour, including the prep work you’ll go through before your infusion. To start, your care team will review your medical history, new or recent symptoms, and current medications. They’ll also take blood samples to check your blood cell counts…

Read the full article at EVERYDAYHEALTH.COM